Intergroupe Francophone De Cancerologie Thoracique
Clinical trials sponsored by Intergroupe Francophone De Cancerologie Thoracique, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for mesothelioma: drug targets cancer from two angles Results expected Sep 2026 (estimated)
- Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer? Results expected Nov 2026 (estimated)
-
New combo therapy aims to boost survival in elderly lung cancer patients
Disease control Recruiting nowThis study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 …
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to stall rare lung cancer
Disease control Recruiting nowThis study tests whether adding an experimental immunotherapy (fianlimab) to standard treatment (cemiplimab plus chemotherapy) can better control pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 126 people who have not yet been treated will receive one…
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for mesothelioma: drug targets cancer from two angles
Disease control Recruiting nowThis phase 2 trial tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer has returned after immunotherapy and chemotherapy. The drug works by blocking blood vessel growth and boosting the immune system to fight cancer. The main goal is to see if the …
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare cancer: tarlatamab takes on chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug tarlatamab can help people with advanced neuroendocrine carcinoma live longer compared to standard chemotherapy. The study plans to enroll 129 participants who have already received prior treatment. Tarlatamab is given as an infusion…
Phase 3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare lung cancer: targeted pill tepotinib faces final test
Disease control Recruiting nowThis Phase 3 trial is testing whether the targeted drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 mutation). About 133 patients who have already tried at least one prior trea…
Phase 3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC